GlassScriptPhysician profile
Nicholas W White
NPI 1437492105
$6,387.64
in general payments reported to CMS, 2019-2025
47 companies · $1,667 in 2025
The $1,667 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $187 · 2022: $658 · 2023: $1,678 · 2024: $2,197 · 2025: $1,667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,368 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,367.98 |
| Education | $173.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $850.60 | 2022-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $583.68 | 2022-2025 | Mounjaro, Zepbound, Emgality |
| Novo Nordisk INC | $537.10 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $520.00 | 2023-2025 | |
| Astellas Pharma US INC | $509.78 | 2022-2025 | Veozah, Myrbetriq |
| Amgen INC. | $428.30 | 2022-2025 | Otezla, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $356.84 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $239.36 | 2022-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $217.38 | 2023-2025 | Rexulti |
| Stryker Corporation | $167.62 | 2024 | Variax, Salvation, Hoffmann |
| Lundbeck LLC | $147.21 | 2024-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $135.03 | 2022-2025 | Capvaxive, Belsomra, Vaxneuvance |
| Janssen Pharmaceuticals, INC | $126.37 | 2023-2025 | Xarelto, Spravato |
| Novartis Pharmaceuticals Corporation | $120.12 | 2023-2025 | |
| Abbott Laboratories | $104.35 | 2022-2025 | Freestyle Libre 3, Proclaim |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $93.15 | 2023-2024 | Cologuard Collection Kit |
| Averitas Pharma INC. | $85.11 | 2023-2025 | Qutenza |
| Daiichi Sankyo INC. | $83.75 | 2022-2024 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $75.75 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.56 | 2022-2025 | Trintellix |
| Glaxosmithkline, LLC. | $70.05 | 2024-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.91 | 2022-2024 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $66.75 | 2022-2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $65.78 | 2022 | |
| Sumitomo Pharma America, INC. | $61.77 | 2025 | Gemtesa |
| Tolmar, INC. | $50.98 | 2023-2024 | |
| Axsome Therapeutics, INC. | $46.54 | 2025 | Sunosi, Auvelity |
| Esperion Therapeutics, INC. | $45.91 | 2024-2025 | Nexletol |
| Endo USA, INC. | $37.60 | 2025 | Xiaflex, Aveed |
| Novavax INC | $37.18 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Dexcom, INC. | $36.82 | 2023-2024 | Dexcom G6 Transmitter |
| Harmony Biosciences LLC | $34.17 | 2024 | |
| Corcept Therapeutics | $30.33 | 2025 | Korlym |
| Smith+Nephew, INC. | $30.25 | 2023-2024 | Collagenase Santyl, Regranex |
| Eisai INC. | $28.36 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $27.96 | 2023-2024 | Austedo Xr |
| Idorsia Pharmaceuticals US INC | $24.62 | 2023 | Quviviq |
| Vifor Pharma, INC. | $23.15 | 2019 | |
| Impel Pharmaceuticals INC. | $21.74 | 2023 | Trudhesa |
| Vanda Pharmaceuticals INC. | $21.48 | 2022 | |
| Phadia US INC. | $17.60 | 2025 | Immunocap |
| Cranial Technologies, INC | $16.59 | 2022 | |
| Antares Pharma, INC. | $15.47 | 2025 | Xyosted |
| Watermark Medical, INC. | $14.80 | 2024 | |
| Sunovion Pharmaceuticals INC. | $14.46 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.42 | 2019 | |
| Mylan Specialty L.P. | $11.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.